BioMarin Pharmaceutical 1 article

The therapeutic identity of BioMarin Pharmaceutical combines rare genetic disease therapeutics and enzyme replacement therapy; the organization operates as a rare-disease biopharmaceutical company. At BioMarin Pharmaceutical, metabolic genetic disease treatment sits alongside phenylketonuria therapeutics; mucopolysaccharidosis enzyme therapy adds disease-specific context to the therapeutic profile. For BioMarin Pharmaceutical, C-type natriuretic peptide analog is retained as a stable scientific attribute, while named products and targets remain separate entities.